NORTHFIELD, Ill. and ALEXANDRIA, Va. – Draft recommendations as part of a focused update to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) evidence-based guideline for human epidermal growth factor receptor 2 (HER2) testing in breast cancer are now open for public comment through June 12, 2017.
ALEXANDRIA, Va. -- The American Academy of PAs (AAPA) and CancerLinQ LLC announced today that they will be entering a partnership, with AAPA contributing expertise to the CancerLinQ® platform and potentially leveraging CancerLinQ Discovery™ for queries that will assist research efforts in the PA community aimed at improving the quality of patient care.
ALEXANDRIA, Va. – An observational study of 826 patients with stage III colon cancer showed that those who consumed two ounces or more of nuts per week had a 42% lower chance of cancer recurrence and 57% lower chance of death than those who did not eat nuts.
ALEXANDRIA, Va. – The targeted therapy gefitinib appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy. In a phase III clinical trial, patients with epidermal growth factor receptor (EGFR)-positive, stage II-IIIA non-small cell lung cancer (NSCLC) who received gefitinib went about 10 months longer without recurrence than patients who received chemotherapy. The study will be presented at the upcoming 2017 ASCO Annual Meeting in Chicago.
ALEXANDRIA, Va. – In one of the first large studies to explore the possible impact of HPV vaccination on oral HPV infections, researchers found it may confer a high degree of protection. The study of young adults in the United States showed that the prevalence of high-risk HPV infection was 88% lower among those who reported getting at least one vaccine dose than among those who were not vaccinated.
ALEXANDRIA, Va. – A phase III randomized clinical trial of 447 patients with biliary tract cancers (BTCs, cancers of the bile duct and gallbladder) showed that giving capecitabine after surgery extends survival by a median of 17 months compared to surgery alone. The finding could provide the basis for a new standard of care in the disease.
ALEXANDRIA, Va. – A study of 992 patients with stage III colon cancer found that those who reported a healthy lifestyle during and following adjuvant (post-surgery) treatment had a 42% lower chance of death and a trend for lower chance of cancer recurrence than those who had less healthy lifestyles. The study will be presented at the upcoming 2017 ASCO Annual Meeting in Chicago.
ALEXANDRIA, Va. – An analysis of nearly 273,000 patients showed that between 2013 and 2014 there was a 1% increase in the percentage of breast, lung, and colorectal cancers diagnosed at the earliest, most treatable stage. Considering the thousands of people diagnosed with these cancers annually, a 1% increase in early-stage diagnosis could add up to a significant number of new cases and potentially lead to better outcomes.
ALEXANDRIA, Va. -- CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Wendy S. Rubinstein, MD, PhD, FACMG, FACP, will be its first Division Director, Clinical Data Management and Curation. Rubinstein will oversee the team working to securely process and analyze the CancerLinQ® platform's patient data from millions of electronic health records to give personalized insights than can improve the quality of care for patients with cancer.
ALEXANDRIA, Va. -- CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), and the College of American Pathologists (CAP) announced today that they will be partnering to bolster the expertise being provided to the CancerLinQ® platform, a real-world, big data initiative focused on cancer patient medical information, aimed at improving the quality of patient care and outcomes.
The American Society of Clinical Oncology (ASCO) congratulates Scott Gottlieb, MD, on his confirmation as Commissioner of the Food and Drug Administration (FDA). With more than 1.7 million new cancer diagnoses made in the United States every year, millions of individuals with cancer and their families rely on the FDA to provide critical oversight and evaluation of the safety and efficacy of new medical products as well as those in routine clinical use.
Alexandria, VA – The American Society of Clinical Oncology (ASCO) has released findings from an ASCO-National Cancer Institute (NCI) collaboration that explored centralizing the development of coverage analyses for multi-site cancer clinical trials. In an ASCO special article published today in the Journal of Oncology Practice, “Feasibility of a Centralized Clinical Trials Coverage Analysis: A Joint Initiative of the American Society of Clinical Oncology and the National Cancer Institute,” the authors assert that developing a centralized system for coverage analysis is a feasible way to address key issues and reduce administrative burdens for cancer research sites managing billing compliance, with potential for widespread benefits across the cancer research field.
ALEXANDRIA, Va. -- CancerLinQ LLC, a wholly-owned nonprofit of the American Society of Clinical Oncology (ASCO), has announced a partnership with the Oncology Nursing Society (ONS). CancerLinQ will draw on ONS's expertise and thought leadership as it continues to provide a robust quality improvement and data-sharing platform to oncology practices and cancer centers. The collaboration builds on the CancerLinQ® Ambassadors Program, which the two organizations launched earlier this year
ASCO applauds members of the House and Senate for their vote this week to provide a $2 billion increase in funding to the National Institutes of Health (NIH). This marks the first time in more than a dozen years that Congress has provided the NIH with a back-to-back funding increase.
ALEXANDRIA, Va. -- CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Santa Clara Valley Medical Center (SCVMC) in San Jose, Calif. has signed an agreement to participate in the CancerLinQ® platform.